TABLE 3.

TEAEs occurring in ≥10% of patients during the interim analysis period of the open‐label extension

Adverse event	2 to <18 years, n = 174, n (%)	18–36 years, n = 73, n (%)	Overall, n = 247, n (%)
Any TEAE	138 (79.3%)	65 (89.0%)	203 (82.2%)
Any SAE	29 (16.7%)	11 (15.1%)	40 (16.2%)
Decreased appetite	28 (16.1%)	12 (16.4%)	40 (16.2%)
Fatigue	23 (13.2%)	10 (13.7%)	33 (13.4%)
Nasopharyngitis	23 (13.2%)	8 (11.0%)	31 (12.6%)
Seizure	16 (9.2%)	11 (15.1%)	27 (10.9%)

Note: Age groups are by entry into the core study.

Abbreviations: SAE, serious adverse event; TEAE, treatment‐emergent adverse event.